The present invention relates to a heterocycle-fused pyrimidine derivative compound or a pharmaceutically acceptable salt thereof, a pharmaceutical composition for preventing or treating diseases related to one or more protein kinases of FLT3, CDK4, CDK6 and HPK1, comprising the same as an active ingredient, and a method for preventing or treating diseases related to one or more protein kinases of FLT3, CDK4, CDK6 and using the same.

This disclosure provides a dry powder formulation of free amino acids with an acceptable and even good taste profile.

Disclosed herein are stabilized powder and aqueous formulations comprising a phospholipid comprising omega fatty acid and a micelle-forming surfactant. In one embodiment, the formulation further comprises a water soluble reducing agent, and/or a metal chelator, and/or a metal bisulfite reducing agent, or combinations thereof, wherein the formulation remains substantially clear and stable when stored at or below room temperature for a period of at least 6 months or at least 12 months; and methods for preparing these formulations.

The present disclosure relates to a composition for treating cancer and inhibiting cancer metastasis, which contains a sulfonamide derivative as an active ingredient. More specifically, the composition containing a sulfonamide derivative as an active ingredient may be provided as a cancer therapeutic agent or a cancer metastasis inhibitor since the sulfonamide derivative from which antibiotic susceptibility has been completely removed exhibits superior effect of inhibiting cancer cell multiplication and migration by effectively inhibiting the secretion of exosomes by cancer cells and exhibits no cytotoxicity to normal cells.

A sweetening or sweetened composition includes sucrose, rubusoside or a rubusoside derivative, and a tannin which may be used in a process for preparing a beverage. Further disclosed is the use of the composition for sweetening beverages as well as for preparing a syrup as a precursor in the preparation of beverages and also as flavoring substance with modifying properties and for reducing the sucrose content in beverages without essentially exhibiting a reduced sweetness sensation. Also disclosed is the use of a combination comprising rubusoside or a rubusoside derivative and a tannin for shortening the lingering sweetness of artificial sweeteners and for shifting the onset of the temporal sweetness sensation of said artificial sweetener towards that of natural sugars.

A method includes ingesting a first portion of a first supplement within three hours prior to boarding an airplane for a flight and ingesting a first portion of a second supplement alongside the first portion of the first supplement, wherein the first portion of the second supplement comprises a probiotic. The method includes ingesting a second portion of the second supplement alongside a first portion of a third supplement during the flight. The method includes ingesting a second portion of the first supplement alongside a second portion of the third supplement within three hours of the airplane landing.

The current invention is directed to a treatment of a proliferative disease comprising administering to a subject in need of such treatment, a composition comprising epigallocatechin-3-gallate (EGCG), curcumin, glucosinolates and, optionally Daikon radish sprout, alone or in combination with providing a ketogenic diet or a modified ketogenic diet to the subject. The invention also provides a composition comprising medium chain triglycerides, Epigallocatechin-3-gallate, curcumin, compositions comprising glucosinolates and/or derivatives thereof, such as glucoraphanin and its breakdown product sulforaphane, (SFN) (which are found at high levels in broccoli sprouts or sprouts of other cruciferous vegetables), and, optionally Daikon radish sprout.

A food product includes a heat-treated vegetable. A content of 3,4-dimethylthiophene (x) in the food product ranges from 0.00035 mg/kg to 3 mg/kg. A content of 2,4-dimethylthiophene (y) in the food product ranges from 0.00015 mg/kg to 3 mg/kg. A content of furfural (z) in the food product ranges from 0.1 mg/kg to 10 mg/kg.

The present invention relates to a pharmaceutical composition or a functional health food comprising a verbenone derivative and pharmaceutically acceptable salts thereof as active ingredients for treating or preventing a neurodegenerative disease. More specifically, the verbenone derivative according to the present invention reduces neuronal cell death and oxidative stress, and is highly effective in preventing ischemic brain damage and inflammatory cell migration in rats, thereby providing the pharmaceutical composition or the functional health food which is useful in treating neurodegenerative diseases.

The invention relates primarily to a method of modulation, preferably of in vitro and/or in vivo modulation, of the cold menthol receptor TRPM8, wherein the receptor is contacted with at least one modulator selected from the group consisting of the compounds of the structure type 1 described herein. The present invention further relates to corresponding uses and compositions comprising such compounds.